which that second also will solidly a review today’s as the attracted us financial with of progress you Thank business high am has within in joining milestones results outreach several that call. I everyone. today on update. quarter investor and has key pleased accomplished cash. review XXXX, business delighted record afternoon, far quarter thus Good I and attention for investment Yvonne. ENDRA enter you, has and ENDRA’s to we Thank level we first XXXX community the am ENDRA growing our positioned
known as TAEUS Acoustic-Enhanced Ultrasound to our advance Technology fronts. on continue We Thermo multiple
stage on NAFLD/NASH fat know, with is the as ultrasound alone accurately liver but liver existing assessment measuring measure early use fat today simple technology enhancing known first tissues application a to it’s TAEUS fatty TAEUS TAEUS Mark we care received NAFLD/NASH, the Last clinicians you XXx to the application ways NAFLD MRI, of to inflammatory proprietary and in affect which for cannot staging billion with FDA. known as disease a XXXk CE platform, non-alcoholic and or lower this clinical year, for and point patient more NAFLD for TAEUS and allows we for in significant is non-alcoholic As liver focused people NASH. We the a an first opportunity indication, than similar its systems, submitted NASH believe of U.S. cost. By of the as application globally. steatohepatitis, also a for visualize at there a
As I mentioned the with last in the be submission to continues call, FDA. the TAEUS our process XXXk on normal conference
for questions the forth levels the to example, part how XXXX. functions other we historical a on naturally, to And In continue relate guidance And are predicate. and process We standard compliance the this FDA extend TAEUS meantime, doesn’t the with clearance our the timing. technology requesting But on they fronts. timeframes arise. the terms to Q&A in the process assure FDA this questions supporting have to securing We information, chosen back consider review by can I information of and been investors, FDA we for optimistic several advance in want the new these technology remain number be like the to with TAEUS. about of provide agency of to in relates FDA’s process how a additional and on responding it as or with
We evaluation sales. to are clinical to commercial independent generate support growing our clinical partnerships data
a We X Europe. these submission. evaluation reminder, in this are the our U.S. sites, X new X to University Bern, to evaluations a and related FDA not As clinical year, partnership in bringing total in Inselspital Switzerland, added our Hospital
Our partner, patients clinically leveraging in look Rocky scanning procedure commercially sites Vista markets and Utah and and we to normal these as levels. hospital all is to forward as return reopen backlogs
This American most drive of other the Chief Thornton, measurement maintaining important Officer, year. AIUM of are We considered present of technology Michael Technology is In areas at for Ultrasound key the Ultrasound clinical to imaging the liver invited is fat. TAEUS and a Madison’s our U.S. Meeting, growing the April, which in Annual cadence by to its Integrative conference, be awareness the activities focused fastest our the to initial ultrasound Institute to of at was Ultrasound TAEUS. world’s four of growth noted presentation focused we modalities. on ultrasound. for for conference And application one many
applications, could also clinical like just liver that for that not masses or the biomarkers things things cancer, to tracking ultrasound first track correlate of acute beyond over that fat. stiffness time, but like tissue be The looking breast foreign to evolution is is outcomes now using ultrasound of
and noteworthy AIUM at intelligence diagnoses. the role area artificial conference second to improve settings, was growing ultrasound The image the obviously of quality
all for capitalize help these up tissue, to treat the is tissue positioned brain for patient big ultrasound noteworthy deceased four sources burn is ultrasound blood placing for ablating to using trend on for or with barrier the an energy about example with And to area the of probe ENDRA without Alzheimer’s. generate directly opening What’s a on investors wave that third focused fourth trends. was example. treat growth to victims, therapeutically, use finally, The or on alternative using ultrasound well
and we liver enhancements ultrasound actively two the areas, application. other sources combining TAEUS of AI leading in are main biomarkers We developing and for our with energy are
as attend technologies learn as worthwhile We as new clinicians also in with temperature to in area, many conferences collaborations. will research property intellectual pharmaceutical participate applications TAEUS to and enables clinical tissue companies ENDRA well have mapping fourth to about therapeutics, our the pursue that and algorithms. continue these them
fact, conferences. collaboration these sites in we In met our of most at Europe U.S. and originated people clinical the with
added the more participation Europe global for active conference of we several XXXX, conferences month, events network we in sales clinical next Association Study built Liver By way, TAEUS ENDRA’s the throughout others broad look as contacts, or have on awareness in each the the the the Disease our that year are of for the balance global year. to several website have leveraging U.S. page attend. substantial and we lists an and clinical plan we We leads. of Given a forward since which and European develop conferences attending X to
our responsibility, to TAEUS representatives recently one and X. two our build team to to commercial team in a continue pan-European in added one bring to and European in bringing We Europe, France market sales more
and partner, mirror traction future clearance, same around independently working gain target plan segments the our U.S. that in sites. the collaboratively each strategy with we clinical to European our current endocrinology. to Upon radiologists XXXk in Healthcare’s we such As on call have and market, looking sales in other evaluation gastrohepatology targeting U.S. representative we as on major and regions country, have representatives sales to ENDRA GE an calling
signing their with NASH. TAEUS This the treatment pharmaceutical to TAEUS Another quarter CRVXXX incorporate technology milestone of Phase partnership our drug was in with and for Xb organizations patient’s significant to is first our upcoming the of in our and of measurement as We Hepion of collaboration technology be first and to and an support will first in used it’s efficiencies collaboration screening study Pharmaceuticals research believe of development. pharmaceutical ways as fat. drive an explore add-on companies biomarker important liver the several contract the
studies, We metabolic effective measure technology, growth clinical user or in fat disease ENDRA will their space for way to pharmaceutical researchers that biomarker partnerships liver opportunity do I as remind also market provide a with the three an additional benefit they can we end ENDRA’s blood pharmaceutical companies today ways. as enable and in believe and you, beyond in cost easy commercial the for a CROs cholesterol the glucose manner.
enrollment screen many companies the I before ENDRA’s inconvenience cost during and pharmaceutical biopsy screen rates failure more phase First, suffer will over that CROs currently incur or patients our to enable of in screening patients And time, MRI. an technology the listeners XX%. companies out or pharmaceutical trial remind efficiently a and
between liver trends identifying trial, provide can liver technology ENDRA’s the and measurements, easier quickly. biopsy measurements and adding dataset during MRI fat more Second, the trial’s to potentially
Finally, to tool are as can treatment. commercially serve identify patients TAEUS for therapy assessment once suitable drugs to approved, help an their monitor use are and to who easy
I very licensed to protect am assets, current to to applications. this as U.S. to two we provide Chief call strengthen issued, on or Commercial continue pending turn total the portfolio issued Renaud, proud property, like over which to current patents, portfolio start that both would technology define grown X we our applications. intellectual our has to activities, that the Earlier details our our the commercialization With and XX IP globally, additional our our of year. the patent Renaud? of filed, more patents issuance Officer update, I to future announced for our since to increased month, which now Turning
